All News

Urologists should watch early adopters of MVPs to know what to expect.

"Our recommendation is to adopt a Mediterranean diet enlisting the help of a dietician, because people absorb nutrients in different ways, depending on the food, the digestive system, the person’s genotype and possibly their microbiome," says Permal Deo, MD.

"Increasing regulation, excess bureaucracy, decreasing autonomy, declining reimbursement, and increased administrative burdens are all increasing the risk of burnout," says Andrew M. Harris, MD.

"The pendulum is swinging back. It’s all about provider education, hammering home the point that we have to do appropriate screening," says urologist Ryan Hankins, MD.

An exploratory analysis of the IMvigor130 study failed to show an improvement in overall survival with atezolizumab, compared with placebo plus platinum-based chemotherapy and gemcitabine in patients with untreated locally advanced or metastatic urothelial cancer.

Treatment with nivolumab in patients with high-risk muscle-invasive urothelial carcinoma continued to improve survival, supporting its use as a standard of following radical resection.

In cohort B of the phase 2 Keynote-057 trial, pembrolizumab led to antitumor activity in patients with BCG-unresponsive, papillary high-risk non–muscle-invasive bladder cancer.

Treatment with rucaparib reduced risk of imaging-based progression or death by half in men with BRCA-altered metastatic castration-resistant prostate cancer.

The ORR for patients was 47%. Of note, ORRs were higher in patients with specific alterations compared with wild type including ERBB2 (67% vs. 44%, respectively; P = .05) and TSC1 (68% vs. 25%; P = .04).

In the the phase 2 HCRN GU 16-257 trial, 33 patients with muscle-invasive bladder cancer were eligible to forego cystectomy and continue 240-mg maintenance nivolumab monotherapy every 2 weeks for 8 cycles followed by surveillance.

Key benefit to expansion of telehealth lies in expanded access.

Nearly three-fourths of physicians doing contract work reported experiencing little to no burnout.

“A majority of patients that present with bladder cancer do not have muscle invasive disease. They have earlier stage, non-muscle invasive, and the NCCN guidelines have detailed guidance for providers about managing those patients,” said Thomas Flaig, MD.

"The interesting thing that's come out of the research that Dr. Lebares has done is that burnout can be countered by mindfulness," said Jennifer M. Taylor, MD, MPH.

An associate professor of Urology at Yale School of Medicine, Dr. Kenney specializes in treating genitourinary cancers, with a particular focus on kidney cancers.

Innovation is at the cornerstone for care in Cleveland Clinic’s Department of Urology, and it’s enabling experts to deliver more personalized approaches to patients.

“Even though we set some priority areas, we also allow practicing urologists to make suggestions for things that they want to know about,” says Amanda North, MD.

"I am prepared and excited to be fully immersed in the health policy work of the AUA as the 2023 Gallagher Scholar," says Denise Asafu-Adjei, MD, MPH.

Amanda North, MD, discusses the AUA census in depth, specifically highlighting the data collected on residents and fellows.

“Almost 1/3 [of telehealth visits] were planned as audio-only, and the healthcare system is no longer going to pay for that. We can use the data from our census to go to Congress and say, 'Hey, you're making a mistake,’” says Amanda North, MD.

Although cases of acute urinary retention and defecation caused by herpes zoster in the sacral area have been reported, no clinical cases about spontaneous bladder rupture have been previously published, according to the authors.

The latest videos from the American Urogynecologic Society (AUGS).

The latest updates from AUGS.

Join the discussion on Health Reform with world leader in health policy and bioethics, Ezekiel J. Emanuel, MD, PhD, the Vice Provost for Global Initiatives and expert panelists and UCSF leaders.

"I have no doubt we’ll become a destination program. We have a great team. Combined with a few key recruitments, we will be set to take our place on the global stage of urology," says Isaac Y. Kim, MD, PhD, MBA, urology professor and chair, Yale Urology.

The symposium brings together clinicians devoted to solving the disease of cancer and the many challenges associated with it.

Access the latest resources from AUGS

Latest events from AUGS